首页 产品中心
  • Bromocriptine Mesylate
    • 甲磺酸溴隐亭;CB-154
    货号: abs813529
    CAS号: 22260-51-1
    分子式: C32H40BrN5O5.CH4O3S
    分子量: 750.7
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs813529-50mg 现货 ¥667.00
    - +
    abs813529-100mg 现货 ¥909.00
    - +
    大包装询价
    产品描述
    描述

    Bromocriptine, an ergoline derivative, is a dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease (PD), hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes.

    纯度
    >98%
    储存/保存方法
    store at -20℃ for one year(Powder);
    in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months.
    基本信息
    别名
    甲磺酸溴隐亭;CB-154
    外观
    white solid
    可溶性/溶解性
    DMSO : ≥ 30 mg/mL
    生物活性
    靶点
    Dopamine Receptor
    In vitro(体外研究)
    Bromocriptine stimulates -GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC50=10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC50>100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC50 value for the interaction of 1.69 μM.
    In vivo(体内研究)
    Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
        提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
        提交不成功?请联系info@absin.cn。
        我要提问

    促销资讯 更多

      订购信息
      您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
      GO
      • 0